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ABSTRACT 
Background: Intragastric administration of the bitter tastant denatonium benzoate inhibits 
the increase of motilin plasma levels and antral contractility. While these findings suggest that 
gastrointestinal bitter taste receptors could be new targets to modulate gastrointestinal 
motility and hormone release, they need confirmation with other bitter receptor agonists. The 
primary aim was to evaluate the effect of intragastric administration of the bitter tastant 
quinine-hydrochloride (QHCl) on motilin and ghrelin plasma levels. Secondly, we studied the 
effect on interdigestive motility. 
Methods: Ten healthy female volunteers were recruited (33±4 years; 22±0.5 kg/m²). Placebo 
or QHCl (10 µmol/kg) was administered intragastrically through a nasogastric feeding tube 
after an overnight fast in a single-blind randomized fashion. Administration started 20 min 
after the first phase III of the migrating motor complex. The measurement continued for 
another 2 hours after the administration. Blood samples were collected every 10 min with the 
baseline sample taken 10 min prior to administration.  
Key results: The increase in plasma levels of motilin (administration; p=0.04) and total ghrelin 
(administration; p=0.02) was significantly lower after QHCl. The fluctuation of octanoylated 
ghrelin was reduced after QHCl (time by administration; p=0.03). Duodenal motility did not 
differ. The fluctuation of antral activity differed over time between placebo and QHCl (time by 
administration; p=0.03). 
Conclusions: QHCl suppresses the increase of both motilin and ghrelin plasma levels. 
Moreover, QHCl reduced the fluctuation of antral motility. These findings confirm the 
potential of bitter taste receptors as targets for modifying interdigestive motility in man.  
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Key points: 
 Intragastric administration of denatonium benzoate modulates gastrointestinal 
behaviour. The effect of other bitter taste receptor agonists on interdigestive 
gastrointestinal function is unknown. 
 Intragastric administration of quinine-hydrochloride reduces the increase of both 
motilin and ghrelin plasma concentrations, as well as the fluctuation of antral motility. 
 Gastric bitter taste receptors could be new targets to modulate gastrointestinal 
motility in health and disease. 
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INTRODUCTION 
In 1916 Carlson first reported the inhibitory effect of intragastric bitter administration on 
fasting gastric contractility in man.(1) Eighty years later Höfer et al. provided the first evidence 
for gastrointestinal taste signalling by reporting the expression of α-gustducin in the gut of 
rats.(2) Further research showed that the bitter taste receptors, taste 2 receptors (TAS2Rs), 
are expressed in the human gastrointestinal tract.(3, 4) Their presence has stimulated 
research to modulate gastrointestinal physiology via the administration of bitter tastants. 
In rats and mice, direct intraluminal administration of bitter agonists inhibited ongoing 
ingestive behaviour and gastric emptying.(4-6) Bitter sham feeding significantly reduced 
gastric emptying of a liquid meal in humans.(7) Gastric emptying of a solid meal was however 
not affected when a bitter tastant was administered directly into the stomach of healthy 
volunteers.(8) Intragastric administration of denatonium benzoate (DB) was shown to inhibit 
gastric accommodation and subsequently food intake.(4) A similar response was observed 
after the intragastric administration of quinine-hydrochloride (QHCl).(9)  
In vitro studies have shown that DB increases the release of cholecystokinine (CCK), glucagon-
like peptide-1 (GLP-1), peptide YY (PYY) and insulin.(10-12) A similar result has been described 
for quinine on the release of GLP-1.(11) However, results obtained in vivo report contradictory 
results. Van Avesaat et. al.(13) reported no significant change in CCK, GLP-1 and PYY after 
intraduodenal infusion of quinine, while another study did report an increase in postprandial 
CCK release after intradoudenal quinine administration.(14) Ghrelin release was not altered 
after intragastric administration of DB in humans.(8) A similar result was obtained for ghrelin 
secretion after intraduodenal administration of quinine.(14) Our group has recently shown 
that intragastric administration of DB inhibited the increase in motilin plasma levels and 
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reduced the occurrence of gastric phase III contractions of the migrating motor complex 
(MMC) in man.(8)  
While these findings suggest that gastrointestinal bitter taste receptors could be new targets 
to modulate gastrointestinal motility and hormone release, they need confirmation with other 
bitter receptor agonists. Therefore, the aim of this study was to evaluate the effect of 
intragastric administration of QHCl on gastrointestinal hormone release and motility during 
the interdigestive state. 
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MATERIAL AND METHODS 
Ethical approval 
This study was approved by the Medical Ethics Committee of the Leuven University Hospital, 
Leuven, Belgium, and performed in full accordance with the Declaration of Helsinki. This trial 
was registered at clinicaltrials.gov as NCT02759926. 
Subjects 
Volunteers were eligible to participate if they were healthy, aged between 18 and 60 years 
old, had a BMI (in kg/m²) ranging from 19.0 to 25.0, and were recruited from an existing 
volunteer database in our group. Exclusion criteria were gastrointestinal diseases, abdominal 
surgery (appendectomy allowed), psychiatric illnesses, and usage of drugs affecting the 
gastrointestinal tract or central nervous system. Only female participants were included since 
it has been reported that sensitivity to intragastrically administered bitter tastants differs 
between men and women.(8) Written informed consent was obtained from all volunteers 
before the start of the study. All subjects were studied after an overnight fast of 12 hours and 
were asked to refrain from smoking at least 1 hour before the start of the study. 
Test compounds 
QHCl was purchased from Fragon (Rotterdam, The Netherlands). Solutions of QHCl were 
prepared in Milli-Q water. The stock concentration for intragastric administration was 100 
mM. A volume of 0.1 ml/kg bodyweight was administered. The dosage of QHCl (10 µmol/kg) 
was chosen based on its inhibitory effect on gastric accommodation in healthy volunteers.(9) 
Vehicle was given during the placebo condition in a volume of 0.1 ml/kg bodyweight.  
Study design 
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After an overnight fast of 12 hours, antroduodenal motility was measured until the occurrence 
of the first phase III contraction. Twenty minutes after the end of phase III, either placebo or 
QHCl (10 µmol/kg bodyweight) was administered intragastrically in a single-blind randomized 
fashion. Intragastric administration was done through a nasogastric feeding tube (Flocare, 
Nutricia, Bornem, Belgium). The feeding tube was placed with its tip in the upper part of the 
stomach and the position was checked with fluoroscopy prior to the start of the study. The 
measurement continued for another two hours after the administration. Blood samples were 
collected every 10 min with the baseline sample taken 10 min prior to administration. 
Antroduodenal manometry Activity of the MMC was measured using a high-resolution solid-
state manometry catheter (36 channels, spaced 1 cm apart, Manoscan 360, Sierra Scientific 
Instruments, Los Angeles, CA, USA, Manoview analysis software v2.0) as described 
previously.(15) Phases of the MMC were identified based on standardized definitions.(16, 17) 
Motility index (MI) was calculated as follows: (number of contractions*average amplitude 
contractions*average duration contractions)/5min.(15, 18, 19) An average MI was calculated 
for the antrum and duodenum by averaging the MI of six consecutive channels. 
Blood collection Blood samples were collected via an intravenous catheter. Samples for motilin 
and ghrelin were collected in lithium heparin and EDTA tubes each containing 500 kIU/ml 
aprotinin (Roche Applied Science, Penzberg, Germany). Samples were centrifuged at 4°C for 
10 min at 1400 x g. Ghrelin plasma samples were immediately acidified to a final concentration 
of 0.1 N HCl and extracted on Sep-Pak C18 columns (Waters Corporation, Milford, MA, USA) 
and vacuum-dried. All plasma samples were stored at -80°C until analysis. Motilin and ghrelin 
(total and octanoylated) plasma levels were determined by radioimmunoassay as fully 
described elsewhere.(6, 15)  
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Statistical analysis 
Significance was set at p<0.05. SAS (Statistical Analysis System version 9.3; SAS Institue) and 
GraphPad Prism (Version 7; GraphPad) were used for the analysis. Data are represented as 
mean±SEM or median (IQR). 
For the hormone plasma levels a percentage change from baseline level was calculated and 
used for the analysis. Mixed model analysis (SAS) was used to assess the main effects of time 
and administration (placebo and QHCl) and their interaction effect on the variables of interest 
(hormone concentrations and MI). Administration and time were entered as within-subject 
categorical variables. Time was also added as a random (subject-specific) intercept. 
The time interval until the occurrence of phase III was compared between the two conditions 
using Wilcoxon signed rank test (GraphPad). The percentage origin of phase III was compared 
between placebo and QHCl with McNemar’s test (GraphPad). For both hormone plasma 
concentrations and antral motility the peak values were determined to correlate the time of 
peak occurrence between antral motility and hormone concentrations. Spearman’s rank 
correlation coefficient (one-tailed) was used for both conditions (GraphPad). 
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RESULTS 
Ten healthy female volunteers were recruited (33±4 years; 22±0.5 kg/m²). None of the 
subjects reported any adverse events after the administration of QHCl. 
Change in hormone plasma levels after quinine-hydrochloride administration 
The effect of intragastric QHCl administration on the change of plasma concentrations of 
motilin and ghrelin (total and octanoylated) was evaluated. Motilin levels were lower after 
QHCL, with a significant main effect of administration (p=0.04) on the percentage change of 
motilin plasma concentrations (Figure 1A). There was no significant effect of time (p=0.2) or a 
significant interaction effect between time and administration (p=0.5). QHCl had a similar 
effect on the change from baseline for total ghrelin plasma levels (Figure 1B). Administration 
had a significant effect (p=0.02), but both time (p=0.7) and the interaction effect between 
administration and time (p=0.1) were non-significant. Although there was no significant effect 
of both administration (p=0.5) or time (p=0.3) on the change of octanoylated ghrelin, there 
was a significant interaction effect between time and administration (p=0.03) (Figure 1C). 
Change in antroduodenal motility after quinine-hydrochloride administration 
Antroduodenal motility was measured using high-resolution manometry (Figure 2). The 
average duration until the occurrence of phase III prior to administration did not differ 
between placebo and QHCl (63 (40-87) min vs 21 (16-90) min; p=0.07). Fifty-six percent of the 
phase III contractions prior to placebo administration and 50% prior to QHCl were of gastric 
origin (p=0.6). 
There was a significant time by administration effect (p=0.03) for antral motility with no 
significant effect of time (p=0.06) or administration (p=0.4) (Figure 3A). Duodenal motility 
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(Figure 3B) was not affected by administration (p=0.2), time (p=0.5) or their interaction effect 
(p=0.6). 
Correlation between motility and peptide plasma levels 
There was a significant positive correlation (r=0.58; p=0.04) between the occurrence of antral 
peak activity and the peak concentration of motilin during the placebo administration (Figure 
4A). A similar result was obtained for octanoylated ghrelin plasma levels (r=0.60; p=0.03). 
There was no significant correlation between the occurrence of antral peak activity and the 
total ghrelin plasma peak (r=-0.42; p=0.1). The positive correlations with the peak 
concentrations of both motilin (r=0.1; p=0.4) and octanoylated ghrelin (r=0.06; p=0.4) were 
lost after QHCl administration (Figure 4B). There was however a significant positive correlation 
between the occurrence of antral peak activity and the peak concentration of total ghrelin 
(r=0.58; p=0.04).  
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DISCUSSION 
Our study showed that intragastric administration of QHCl suppresses interdigestive 
gastrointestinal motor function and release of motilin and ghrelin. These results confirm our 
previous findings that intragastric bitter administration alters interdigestive functions of the 
gastrointestinal tract.(8) 
Quinine binds to 9 different TAS2Rs (TAS2R4, TAS2R7, TAS2R10, TAS2R14, TAS2R39, TAS2R40, 
TAS2R43, TAS2R44, TAS2R46). Five of these receptors also bind DB (TAS2R4, TAS2R10, 
TAS2R39, TAS2R43, TAS2R46).(20) The difference in receptor activation might be an 
explanation for the different effect of QHCl and DB on ghrelin release. We previously reported 
that intragastric administration of DB inhibited the release of motilin, but had no effect on 
ghrelin.(8) Intragastric administration of QHCl however inhibited the release of both motilin 
and ghrelin. A discrepancy between intragastric DB and QHCl administration on ghrelin release 
has already been described in mice.(6) However, oral gavage of QHCl had no effect on ghrelin 
release in mice, while DB caused an increase. These results show that bitter agonists might 
have different effects in different species. 
Our study showed that intragastric administration of 10 µmol/kg QHCl inhibited the release 
of total (desoctanoyl and octanoyl) ghrelin and reduced the fluctuation of octanoylated 
ghrelin. Two cell types have been described that secrete ghrelin, a cell type containing both 
octanoylated and desoctanoylated ghrelin and another cell type containing only 
desoctanoylated ghrelin.(6) The octanoylation of ghrelin is caused by a posttranslational 
esterification of the third serine residue by ghrelin O-acyltransferase (GOAT).(21) A possible 
explanation for the different effect of QHCl on the plasma concentration of octanoylated vs. 
unacylated ghrelin could be a difference in the expression of TAS2Rs on the ghrelin secreting 
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cell types. So far, the expression of TAS2R4 and TAS2R10 has been shown in mucosal tissue 
from the fundus and small intestine in humans.(22) However, co-expression of TAS2Rs and 
ghrelin secreting cells has not been shown to date. Another possibility could be that the 
transduction pathway after QHCl administration also affects the expression of GOAT causing 
a discrepancy between total and octanoylated ghrelin. Further research is needed to specify 
the mechanism by which QHCl influences ghrelin secretion. 
A previous study, where quinine (18 mg) was administered intraduodenally, showed that 
there was no effect on ghrelin release.(14) The dosage given in the current study is higher, 
which may account for some of the different effects. Moreover, ghrelin secreting cells are 
mainly located in the oxyntic mucosa of the stomach, so bypassing the stomach via 
intraduodenal administration could abolish the effects of quinine on ghrelin secretion.(23)  
The inhibition of motilin release after intragastric bitter administration is seen after both DB 
and QHCl administration. Moreover, the correlation between motilin and antral motility is lost 
after both bitter administrations.(8) Interdigestive antral motility in man is regulated by 
motilin.(15) The inhibitory effect of bitter administration on antral motility might therefore be 
mediated by its effect on motilin release. However, in the present study we also found a 
significant correlation between peak activity of antral motility and octanoylated ghrelin, which 
was lost after QHCl administration. Although endogenous ghrelin plasma concentrations were 
not found to fluctuate with the different phases of the MMC, exogenous administration of 
octanoylated ghrelin is known to induce a gastric phase III contraction.(24) Nevertheless, the 
effect of desoctanoylated ghrelin was not investigated. In rats it has been shown that desacyl 
ghrelin disrupts fasting gastrointestinal motility.(25) In suncus murinus, a small laboratory 
animal model, ghrelin has been identified as an essential factor for the motilin-induced gastric 
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contractions.(26) A similar synergistic effect between motilin and ghrelin might therefore be 
present in humans. After QHCl administration antral motility seems to be controlled by total 
ghrelin since the positive correlation with motilin and octanoylated ghrelin was abolished. 
Although this correlation shows that the timing of total ghrelin correlates with the timing of 
antral peak activity, it does not say anything about the strength of antral contractility. 
Moreover, a direct effect of QHCl on smooth muscle cells of the gastrointestinal tract cannot 
be excluded. The presence of TAS2Rs and their associated G-proteins has been shown in 
human gastric smooth muscle cells.(4) Further research is necessary to determine via which 
pathway bitter agonists modulate gastrointestinal behavior. 
MMC cycle length varies significantly between subjects.(16) Also in the current study antral 
MI varied significantly between subjects, as seen by the high error flags in the placebo 
condition. This is due to the different onset of phase III contractions between subjects. The 
variability in antral MI after QHCl administration was diminished compared to placebo. This 
decrease in variability is probably due to a delay in the occurrence of phase III. However, with 
the current protocol we did not consistently continue to measure until the next phase III after 
administration so this cannot be confirmed just on the basis of the current study.  
In conclusion, our study confirms the inhibitory effect of intragastric bitter administration on 
interdigestive gastrointestinal behavior in humans. Although future studies are warranted to 
determine the pathway by which bitter agonists modulate gastrointestinal function, these 
findings show that bitter taste receptors could be used as new targets to modulate 
gastrointestinal activity. 
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FIGURE LEGENDS 
Figure 1. The effect of intragastric QHCl administration on motilin and ghrelin plasma 
concentrations. Plasma concentrations were measured using hormone-specific 
radioimmunoassays. Data are represented as percentage change from baseline (10 min prior 
to administration). (A) Percentage change of motilin plasma levels differed between the two 
conditions (p=0.04). (B) Percentage change of total ghrelin plasma levels differed between the 
two conditions (p=0.02). (C) Percentage change of octanoylated ghrelin plasma levels. 
Significant time by administration effect (p=0.03). Data are represented as mean±SEM. *: 
p<0.05 
Figure 2. High-resolution manometry of antroduodenal contractility. Pressure topography 
image of a measurement during intragastric placebo (A) and quinine-hydrochloride (B) 
administration. Pressure intensity is colour coded with low pressures represented by the blue 
spectrum and high pressures by the red spectrum. Intragastric administration (vertical line) 
started 20 min after the end of phase III. Antroduodenal motility was measured for another 2 
hours after the administration. Arrows indicate phase III contractions. Both conditions 
represent measurements of antroduodenal activity in the same subject on separate occasions.  
Figure 3. The effect of intragastric QHCl administration on antral and duodenal motility. 
Motility index was calculated by averaging the motility index of six consecutive antral or 
duodenal channels. (A) Antral motility showed a significant time by administration interaction 
effect (p=0.03). (B) Duodenal motility was not affected by the administration of quinine-
hydrochloride. Data are represented as mean±SEM. 
Figure 4. Correlation between antral peak activity and plasma peak concentration. Time 
interval until the maximum value was determined for both antral motility and hormone 
Deloose et al 20 
 
concentrations. (A) Correlation for the placebo condition. (B) Correlation for the quinine-
hydrochloride condition. Solid line represents regression curve for octanoylated ghrelin. 
Striped line represent regression curve for total ghrelin. Dotted line represents regression 
curve for motilin. MI: motility index 
